Journal of Clinical & Experimental Oncology

Short Communication A SCITECHNOL JOURNAL

Analyzing Tumor Immunology Mechanisms and Therapeutic Strategies

Matthew Galen*

Department of Oncology, Yale University, New Haven, United States of America

***Corresponding Author:** Wein Zennh, Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, China; E-mail: matthew_galen@yu31.edu

Received date: 25 March, 2024, Manuscript No. JCEOG-24-136981;

Editor assigned date: 27 March, 2024, PreQC No. JCEOG-24-136981 (PQ);

Reviewed date: 10 April, 2024, QC No. JCEOG-24-136981;

Revised date: 17 April, 2024, Manuscript No. JCEOG-24-136981 (R);

Published date: 24 April, 2024, DOI: 10.4172/2324-9110.1000406

Description

Tumor immunology, an emerging field in cancer, focuses on understanding the interactions between the immune system and cancer cells. This discipline has revolutionized oncology by introducing new therapeutic strategies that stimulate the body's immune system to fight cancer [1]. It delves into the mechanisms of tumor immunology and the therapeutic strategies emerging from this field, showing their significance in modern cancer treatment [2]. Tumor immunology studies how the immune system interacts with tumor cells, recognizing and eliminating them. This complex involves various immune cells, signaling molecules, and the tumor microenvironment. Understanding these interactions is essential for developing effective immunotherapies [3].

The immune system continuously interaction monitors and eliminates abnormal cells, a process known as immune surveillance. However, cancer cells can evade this surveillance through several mechanisms [4]. Tumors can upregulate checkpoint proteins like PD-L1, which bind to PD-1 receptors on T-cells, inhibiting their activity and allowing cancer cells to escape immune destruction. Tumors develop an immunosuppressive microenvironment by recruiting Regulatory T-cells (Tregs) and Myeloid-Derived Suppressor Cells (MDSCs), which inhibit the anti-tumor immune response [5]. Cancer cells can mutate or downregulate the expression of tumor antigens, making them less recognizable to the immune system.

The immune system consists of innate and adaptive components that work together to combat cancer. Natural killer (NK) cells, macrophages, and Dendritic Cells (DCs) are part of the innate immune system [6]. NK cells can directly kill tumor cells, while macrophages and DCs present tumor antigens to T-cells, initiating an adaptive immune response. T-cells and B-cells constitute the adaptive immune system. Cytotoxic T-lymphocytes (CTLs) can specifically target and kill cancer cells presenting tumor antigens, while B-cells produce antibodies that mark cancer cells for destruction [7].

Immune checkpoint inhibitors these therapies block inhibitory pathways that prevent T-cells from attacking cancer cells. By inhibiting proteins like PD-1, PD-L1, and CTLA-4, checkpoint inhibitors unleash the immune response against tumors. Drugs like Pembrolizumab (Keytruda) and Nivolumab (Opdivo) have shown significant success in treating various cancers, including melanoma and non-small cell lung cancer. Chimeric Antigen Receptor (CAR) T-cell therapy involves genetically engineering a patient's T-cells to express receptors specific to cancer antigens [8]. These modified T-cells are then expanded and infused back into the patient, where they seek and destroy cancer cells. CAR-T therapies, such as Tisagenlecleucel (Kymriah) and Axicabtagene ciloleucel (Yescarta), have demonstrated remarkable efficacy in treating certain hematologic malignancies.

Cancer Vaccines aim to stimulate the immune system to recognize and attack cancer cells. Preventive Vaccines these are designed to prevent cancer development, such as the HPV vaccine, which protects against cervical cancer. Therapeutic vaccines these target existing cancer by enhancing the body's immune response. Sipuleucel-T (Provenge) is an example, used to treat prostate cancer by stimulating an immune response against Prostatic Acid Phosphatase (PAP), a protein expressed by prostate cancer cells. Adoptive Cell Transfer (ACT) this strategy involves isolating Tumor-infiltrating Lymphocytes (TILs) from a patient's tumor, expanding them in the laboratory, and reinfusing them into the patient [9].

This approach has shown potential in treating melanoma and other cancers. The expanded TILs can effectively target and kill cancer cells within the patient's body. Oncolytic Virus therapy in which oncolytic viruses selectively infect and kill cancer cells while sparing normal cells [10]. These viruses can also stimulate an anti-tumor immune response. Talimogene laherparepvec an engineered herpes simplex virus, is an approved oncolytic virus therapy for melanoma.

Conclusion

Tumor immunology has transformed the way of cancer treatment, providing belief for long-term remission and even cures for certain cancers. Understanding the mechanisms by which the immune system interacts with cancer cells has led to innovative therapeutic strategies, such as immune checkpoint inhibitors, CAR-T cell therapy, and cancer vaccines. While challenges remain, ongoing studies and advancements in this field aim to refine and expand the variety of immunotherapies, ultimately improving outcomes for cancer patients worldwide.

References

1. Darekar S, Georgiou K, Yurchenko M, Yenamandra SP, Chachami G, et al. Epstein-Barr virus immortalization of human B-cells leads to stabilization of hypoxia-induced factor 1 alpha, congruent with the Warburg effect.
2. Mhaidly R, Mechta-Grigoriou F (2021) Role of cancer-associated fibroblast subpopulations in immune infiltration, as a new means of treatment in cancer. Immunol Rev 302(1): 259-272.
3. Mao X, Xu J, Wang W, Liang C, Hua J, et al. (2021) Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: New findings and future perspectives. Mol cancer 20(1):1-30.
4. Cao X, Shores EW, Hu-Li J, Anver MR, Kelsail BL, et al.(1995) Defective lymphoid development in mice lacking expression of the common cytokine receptor γ chain. Immunity 2(3):223-238.

5. Yoshida GJ (2020) Applications of patient-derived tumor xenograft models and tumor organoids. J Hematol Oncol 13(1): 1-6.
6. Blomme A, van Simaeys G, Doumont G, Costanza B, Bellier J, et al. (2018) Murine stroma adopts a human-like metabolic phenotype in the PDX model of colorectal cancer and liver metastases. Oncogene 37(9):1237-1250.
7. Linxweiler J, Hajili T, Körbel C, Berchem C, Zeuschner P, et al. (2020) Cancer-associated fibroblasts stimulate primary tumor growth and metastatic spread in an orthotopic prostate cancer xenograft model. Sci Rep 10(1):12575.
8. Sahai E, Astsaturov I, Cukierman E, DeNardo DG, Egeblad M, et al. (2020) A framework for advancing our understanding of cancer-associated fibroblasts. Nat Rev Cancer 20(3):174-186.
9. Sun H, Cao S, Mashl RJ, Mo CK, Zaccaria S, et al. (2021) Comprehensive characterization of 536 patient-derived xenograft models prioritizes candidates for targeted treatment. Nat Commun 12(1):5086.
10. Kanaki Z, Voutsina A, Markou A, Pateras IS, Potaris K, et al. (2021) Generation of non-small cell lung cancer patient-derived xenografts to study intratumor heterogeneity. Cancers 13(10): 2446.